The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors
Standard
The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors. / Oing, Christoph; Lorch, Anja.
in: ONCOL RES TREAT, Jahrgang 41, Nr. 6, 2018, S. 365-369.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors
AU - Oing, Christoph
AU - Lorch, Anja
N1 - © 2018 S. Karger GmbH, Freiburg.
PY - 2018
Y1 - 2018
N2 - Germ cell tumors (GCT) are a unique tumor entity with excellent cure rates if guideline-endorsed treatment is thoroughly applied. Even patients with widespread metastatic disease can often be cured with cisplatin-based combination chemotherapy as part of a multimodal treatment approach. However, about 30% of patients with metastatic disease at initial presentation, corresponding to about 5-10% of all GCT patients, relapse or progress despite first-line treatment and therefore require salvage chemotherapy. Salvage systemic treatment either consists of conventional-dose cisplatin-based combination chemotherapy or sequential high-dose treatment with carboplatin and etoposide plus subsequent autologous stem cell support. This review is based on a comprehensive literature search of MEDLINE and conference proceedings of ESMO, ASCO, and EAU meetings until 2018 and provides an overview of current treatment options for germ cell cancer patients relapsing after or progressing during first-line cisplatin-based combination chemotherapy.
AB - Germ cell tumors (GCT) are a unique tumor entity with excellent cure rates if guideline-endorsed treatment is thoroughly applied. Even patients with widespread metastatic disease can often be cured with cisplatin-based combination chemotherapy as part of a multimodal treatment approach. However, about 30% of patients with metastatic disease at initial presentation, corresponding to about 5-10% of all GCT patients, relapse or progress despite first-line treatment and therefore require salvage chemotherapy. Salvage systemic treatment either consists of conventional-dose cisplatin-based combination chemotherapy or sequential high-dose treatment with carboplatin and etoposide plus subsequent autologous stem cell support. This review is based on a comprehensive literature search of MEDLINE and conference proceedings of ESMO, ASCO, and EAU meetings until 2018 and provides an overview of current treatment options for germ cell cancer patients relapsing after or progressing during first-line cisplatin-based combination chemotherapy.
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Cisplatin/administration & dosage
KW - Dose-Response Relationship, Drug
KW - Hematopoietic Stem Cell Transplantation/methods
KW - Humans
KW - Male
KW - Neoplasm Recurrence, Local
KW - Neoplasms, Germ Cell and Embryonal/drug therapy
KW - Salvage Therapy/methods
KW - Testicular Neoplasms/drug therapy
U2 - 10.1159/000489135
DO - 10.1159/000489135
M3 - SCORING: Review article
C2 - 29843143
VL - 41
SP - 365
EP - 369
JO - ONCOL RES TREAT
JF - ONCOL RES TREAT
SN - 2296-5270
IS - 6
ER -